Assessing the value of novel antimicrobials under new payment models
Assessing the value of novel antimicrobials under new payment models
This work follows on from a major study undertaken by EEPRU under the 2011-18 contract (see report below), where a framework was developed to assess the value of innovative antimicrobials under novel payment arrangements being developed by the NHS.
During 2021-22 we used the framework to evaluate the benefits and cost-effectiveness of two specific antimicrobials as part of a NICE assessment and appraisal process, which culminated in recommendations from the National Institute for Health and Care Excellence and commercial payment arrangements between the respective manufacturers and NHSE&I.
To work closely with NICE, NHSE&I and DHSC to identify methods research questions relating to the evaluation of innovative antimicrobials and address priority questions.
To apply the recently-developed evaluation framework to two specific antimicrobials as part of a NICE assessment and appraisal process.
Mark Sculpher, Beth Woods, Laetitia Schmitt, Claire Rothery, Dina Jankovic, Laura Bojke, Sue Harnan, Ben Kearns and Ruth Wong
Mark Sculpher
mark.sculpher@york.ac.uk
CAZ-AVI
Harnan, S., Kearns, B., Scope, A., Schmitt, L., Jankovic, D., Hamiltonm J., Wong, R., Srivastava, T., Hill H, Chang Ku, C., Ren, K., Rothery, C., Bojke, L., Sculpher, M., Woods, B. (2022) Final report for the technology evaluation of ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections. Policy Research Unit in Economic Evaluation of Health and Care Interventions. Universities of Sheffield and York. EEPRU Research Report 067. DOI: https://doi.org/10.15131/shef.data.25219274
CEFI
Woods, B., Schmitt, L., Jankovic, D., Kearns, B., Scope, A., Ren, K., Wong, R., Srivastava, T., Chang Ku, C., Hamiltonm J., Rothery, C., Bojke, L., Sculpher, M., Harnan, S. (2022) Final report for the technology evaluation of cefiderocol for treating severe aerobic Gram-negative bacterial infections. Policy Research Unit in Economic Evaluation of Health and Care Interventions. Universities of Sheffield and York. EEPRU Research Report 068. DOI: https://doi.org/10.15131/shef.data.25219307
Rothery, C., Woods, B., Schmitt, L., Claxton, K., Palmer, S., Sculpher, M. (2018) Framework for value assessment of new antimicrobials. Implications of alternative funding arrangements for NICE Appraisal (PDF, 4MB). Policy Research Unit in Economic Evaluation of Health and Care Interventions. Universities of Sheffield and York. EEPRU Research Report 059. DOI: https://doi.org/10.15131/shef.data.25219094
Woods, B., Kearns, B., Schmitt, L. et al. Assessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime-Avibactam to Inform Delinked Payments by the NHS in England. Appl Health Econ Health Policy (2024). https://doi.org/10.1007/s40258-024-00924-x
Woods B, Schmitt L, Jankovic D, Kearns B, Scope A, Ren S, Srivastava T, Ku CC, Hamilton J, Rothery C, Bojke L, Sculpher M, Harnan S. Cefiderocol for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model. Health Technol Assess. 2024 Jun;28(28):1-238. doi: 10.3310/YGWR4511. PMID: 38938145; PMCID: PMC11229178.
Woods, B., Lomas, J., Sculpher, M., Weatherly, H., & Claxton, K. (2024). Achieving dynamic efficiency in pharmaceutical innovation: Identifying the optimal share of value and payments required. Health Economics, 1–16. https://doi.org/10.1002/hec.4795